EA201590687A1 - Лечение легкой и умеренной болезни альцгеймера - Google Patents
Лечение легкой и умеренной болезни альцгеймераInfo
- Publication number
- EA201590687A1 EA201590687A1 EA201590687A EA201590687A EA201590687A1 EA 201590687 A1 EA201590687 A1 EA 201590687A1 EA 201590687 A EA201590687 A EA 201590687A EA 201590687 A EA201590687 A EA 201590687A EA 201590687 A1 EA201590687 A1 EA 201590687A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- alzheimer
- lung
- modern disease
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261710229P | 2012-10-05 | 2012-10-05 | |
| PCT/US2013/062964 WO2014055588A1 (en) | 2012-10-05 | 2013-10-02 | Treatment of mild and moderate alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201590687A1 true EA201590687A1 (ru) | 2015-09-30 |
Family
ID=49354960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201590687A EA201590687A1 (ru) | 2012-10-05 | 2013-10-02 | Лечение легкой и умеренной болезни альцгеймера |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2903606A1 (https=) |
| JP (2) | JP6566868B2 (https=) |
| KR (1) | KR20150064743A (https=) |
| CN (2) | CN110292638A (https=) |
| AU (2) | AU2013327450B2 (https=) |
| BR (1) | BR112015007641A8 (https=) |
| CA (1) | CA2886785C (https=) |
| EA (1) | EA201590687A1 (https=) |
| HK (1) | HK1207004A1 (https=) |
| IL (1) | IL237730B (https=) |
| IN (1) | IN2015DN03734A (https=) |
| MX (1) | MX377733B (https=) |
| NZ (2) | NZ705813A (https=) |
| SG (2) | SG10201702648YA (https=) |
| WO (1) | WO2014055588A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190823A1 (en) * | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2020076668A1 (en) | 2018-10-10 | 2020-04-16 | Vtv Therapeutics Llc | Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine |
| WO2020086388A1 (en) * | 2018-10-22 | 2020-04-30 | Vtv Therapeutics Llc | Glucokinase activator compositions for the treatment of cognitive impairment |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| CN114031687B (zh) * | 2021-11-12 | 2022-06-07 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1482931T3 (da) * | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE |
| WO2005000295A1 (en) * | 2003-05-20 | 2005-01-06 | Transtech Pharma, Inc. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| EP1707203A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
| CN101663280A (zh) * | 2007-04-05 | 2010-03-03 | 转化技术制药公司 | [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ |
| CA2681864A1 (en) * | 2007-04-05 | 2008-10-16 | Transtech Pharma, Inc. | Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine |
| US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
| US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
| US8933040B2 (en) * | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
-
2013
- 2013-10-02 NZ NZ705813A patent/NZ705813A/en unknown
- 2013-10-02 MX MX2015003732A patent/MX377733B/es active IP Right Grant
- 2013-10-02 KR KR1020157011366A patent/KR20150064743A/ko not_active Ceased
- 2013-10-02 EP EP13776676.2A patent/EP2903606A1/en not_active Withdrawn
- 2013-10-02 WO PCT/US2013/062964 patent/WO2014055588A1/en not_active Ceased
- 2013-10-02 IN IN3734DEN2015 patent/IN2015DN03734A/en unknown
- 2013-10-02 HK HK15107776.8A patent/HK1207004A1/xx unknown
- 2013-10-02 JP JP2015535750A patent/JP6566868B2/ja active Active
- 2013-10-02 CN CN201910466681.3A patent/CN110292638A/zh active Pending
- 2013-10-02 SG SG10201702648YA patent/SG10201702648YA/en unknown
- 2013-10-02 CA CA2886785A patent/CA2886785C/en active Active
- 2013-10-02 CN CN201380051206.0A patent/CN104703592A/zh active Pending
- 2013-10-02 AU AU2013327450A patent/AU2013327450B2/en active Active
- 2013-10-02 NZ NZ739521A patent/NZ739521A/en unknown
- 2013-10-02 EA EA201590687A patent/EA201590687A1/ru unknown
- 2013-10-02 BR BR112015007641A patent/BR112015007641A8/pt active Search and Examination
- 2013-10-02 SG SG11201502210VA patent/SG11201502210VA/en unknown
-
2015
- 2015-03-12 IL IL237730A patent/IL237730B/en active IP Right Grant
-
2018
- 2018-05-16 AU AU2018203434A patent/AU2018203434A1/en not_active Abandoned
-
2019
- 2019-05-23 JP JP2019096786A patent/JP6894940B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015007641A2 (pt) | 2017-07-04 |
| EP2903606A1 (en) | 2015-08-12 |
| AU2013327450A1 (en) | 2015-05-14 |
| AU2018203434A1 (en) | 2018-06-07 |
| CA2886785A1 (en) | 2014-04-10 |
| SG10201702648YA (en) | 2017-04-27 |
| CN110292638A (zh) | 2019-10-01 |
| IN2015DN03734A (https=) | 2015-09-18 |
| WO2014055588A1 (en) | 2014-04-10 |
| JP2015535850A (ja) | 2015-12-17 |
| CA2886785C (en) | 2022-06-07 |
| JP6894940B2 (ja) | 2021-06-30 |
| IL237730B (en) | 2018-10-31 |
| SG11201502210VA (en) | 2015-04-29 |
| NZ705813A (en) | 2018-02-23 |
| MX377733B (es) | 2025-03-11 |
| JP6566868B2 (ja) | 2019-08-28 |
| CN104703592A (zh) | 2015-06-10 |
| BR112015007641A8 (pt) | 2018-04-03 |
| HK1207004A1 (zh) | 2016-01-22 |
| NZ739521A (en) | 2019-06-28 |
| MX2015003732A (es) | 2015-09-23 |
| JP2019163301A (ja) | 2019-09-26 |
| AU2013327450B2 (en) | 2018-07-12 |
| KR20150064743A (ko) | 2015-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA114726C2 (uk) | 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| NZ716487A (en) | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
| UA108369C2 (uk) | Піролопіримідини як інгібітори cdk4/6 | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| WO2015031564A3 (en) | Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors | |
| EA201490774A1 (ru) | Новые производные оксазина и их применение при лечении заболевания | |
| UA113051C2 (xx) | Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів | |
| EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
| EA201200686A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера | |
| EA201391566A1 (ru) | Комбинации активных соединений, содержащие производное соединение (тио)карбоксамида и фунгицидное соединение | |
| EA201290836A1 (ru) | Связанные бис-арильные арилтриазолоны и их применение | |
| EA201490103A1 (ru) | Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1 | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| EA201290952A1 (ru) | Химические соединения | |
| EA201200176A1 (ru) | Производные оксазина и их применение для лечения неврологических нарушений | |
| EA201790653A1 (ru) | Способ лечения болезни альцгеймера и других расстройств | |
| EA201590687A1 (ru) | Лечение легкой и умеренной болезни альцгеймера | |
| EA201690386A1 (ru) | Соединения и композиции в качестве ингибиторов mek | |
| WO2013061004A8 (fr) | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines | |
| EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
| EA201590735A1 (ru) | 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств | |
| EA201390984A1 (ru) | Гетероциклические соединения, подходящие для лечения дислипидемии | |
| EA201591180A1 (ru) | Составы ингибитора lfa-1 |